TAUNS LaboratoriesTAUNS Laboratories, Inc.197A東証スタンダード医薬品FY ending Jun 2026, non-consolidated, J-GAAP

TAUNS Laboratories FY ending Jun 2026 results

TAUNS Laboratories brought in ¥14.4B in revenue.

Out of every ¥100 of sales, about ¥29 is left as operating profit.

Revenue changed -22.9% from the prior year, operating profit -49.2%.

Revenue and profit pattern

Revenue and profit down

Revenue -22.9% · profit -49.2%, calculated from disclosed figures.

Operating leverage: 2.15× (profit growth ÷ revenue growth)

FY ending Jun 2025 → FY ending Jun 2026

FY ending Jun 2025 → FY ending Jun 2026

For every ¥100 TAUNS Laboratories sells, how much goes where, and how much is kept.

FY ending Jun 2026

Gross margin61.4%

Operating margin29.2%

Net margin38.2%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第11期(2025/07/01－2026/06/30)
ID S100Z3TC2026-09-24Open
EDINET (FSA Japan)
有価証券報告書－第10期(2024/07/01－2025/06/30)
ID S100WRAR2025-09-25Open
EDINET (FSA Japan)
有価証券報告書－第9期(2023/07/01－2024/06/30)
ID S100UG3E2024-09-27Open

Extracted from XBRL: 47 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.